Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pyrimidine SCHEMBL44064 | 1.00 | TSHR (0.40) | TSHRNAPRTTDP1CYP2A6CYP11B2 | |
| Pyrimidine SCHEMBL5662611 | 1.00 | — | — | |
| Pyrimidine SCHEMBL7196249 | 1.00 | TSHR (0.40) | TSHRNAPRTTDP1CYP2A6CYP11B2 | |
| Pyrimidine SCHEMBL1846 | 0.87 | — | — | |
| Pyrimidine SCHEMBL19437633 | 0.87 | TSHR (0.50) | TSHRNAPRTTDP1CYP2A6 | |
| Pyrimidine SCHEMBL10646 | 0.87 | TSHR (0.50) | TSHRNAPRTTDP1CYP2A6 | |
| Pyrimidine SCHEMBL9545353 | 0.82 | — | — | |
| Pyrimidine SCHEMBL22346941 | 0.82 | — | — | |
| Pyrimidine SCHEMBL21315895 | 0.82 | TSHR (0.46) | TSHRNAPRTTDP1CYP2A6 | |
| Pyrimidine SCHEMBL383109 | 0.82 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170129898-A1 | PROCESS FOR THE PREPARATION OF TRIAZOLO[4,5-D] PYRIMIDINE CYCLOPENTANE COMPOUNDS | FLAMMA SPA (IT) | 2017-05-11 | — | — | US | disclosed |
| EP-3157907-A1 | PROCESS FOR THE PREPARATION OF TRIAZOLO[4,5-D]PYRIMIDINE CYCLOPENTANE COMPOUNDS | Flamma S.P.A. (IT) | 2017-04-26 | — | — | EP | disclosed |
| WO-2015193165-A1 | PROCESS FOR THE PREPARATION OF TRIAZOLO[4,5-D] PYRIMIDINE CYCLOPENTANE COMPOUNDS | FLAMMA SPA (IT) | 2015-12-23 | — | — | WO | disclosed |
| WO-2015193165-A1 | PROCESS FOR THE PREPARATION OF TRIAZOLO[4,5-D] PYRIMIDINE CYCLOPENTANE COMPOUNDS | FLAMMA SPA (IT) | 2015-12-23 | — | — | WO | disclosed |
| US-20150197496-A1 | PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2015-07-16 | — | — | US | disclosed |
| EP-2404907-B1 | Pyrimidyl cyclopentanes as AKT protein kinase inhibitors | ARRAY BIOPHARMA INC (US) | 2015-01-14 | — | — | EP | disclosed |
| EP-2173723-B3 | PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2014-11-19 | — | — | EP | disclosed |
| US-20140315887-A1 | PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | GENENTECH, INC. | 2014-10-23 | — | — | US | disclosed |
| US-8846683-B2 | Pyrimidyl cyclopentanes as Akt protein kinase inhibitors | ARRAY BIOPHARMA, INC. (US) | 2014-09-30 | — | — | US | disclosed |
| CN-103965158-A | Preparation method for intermediate used for synthesis of triazolo[4,5-d]pyrimidine cyclopentane compound | SHANGHAI INST PHARM INDUSTRY | 2014-08-06 | — | — | CN | disclosed |
| CN-103429576-A | Novel processes for preparing triazolo[4,5-d]pyrimidine derivatives and intermediates thereof | ACTAVIS GROUP PTC EHF | 2013-12-04 | — | — | CN | disclosed |
| US-20130143865-A1 | PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | GENENTECH, INC. (US) | 2013-06-06 | — | — | US | disclosed |
| CN-103003231-A | Novel method for preparing phenylcyclopropylamine derivatives and use thereof for preparing ticagrelor | ACTAVIS GROUP PTC EHF | 2013-03-27 | — | — | CN | disclosed |
| US-8377937-B2 | Pyrimidyl cyclopentanes as AKT protein kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2013-02-19 | — | — | US | disclosed |
| EP-2404907-A1 | Pyrimidyl cyclopentanes as AKT protein kinase inhibitors | Array Biopharma, Inc. (US) | 2012-01-11 | — | — | EP | disclosed |
| EP-2173723-B1 | PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2011-08-31 | — | — | EP | disclosed |
| US-20110160221-A1 | PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2011-06-30 | — | — | US | disclosed |
| EP-2173723-A1 | PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | Array Biopharma, Inc. (US) | 2010-04-14 | — | — | EP | disclosed |
| WO-2009006569-A1 | PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2009-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150197496-A1 | PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | TK1, PIK3CA, AKT1 | TSHR 4004/4885NAPRT 1279/4885TDP1 444/4885 |
| US-20140315887-A1 | PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | TK1, PIK3CA, AKT1 | TSHR 4004/4885NAPRT 1279/4885TDP1 444/4885 |
| US-20130143865-A1 | PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | TK1, PIK3CA, AKT1 | TSHR 4004/4885NAPRT 1279/4885TDP1 444/4885 |
| US-20110160221-A1 | PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | TK1, PIK3CA, AKT1 | TSHR 4004/4885NAPRT 1279/4885TDP1 444/4885 |
| US-20170129898-A1 | PROCESS FOR THE PREPARATION OF TRIAZOLO[4,5-D] PYRIMIDINE CYCLOPENTANE COMPOUNDS | TBXA2R, THPO, P2RY4 | TSHR 1709/4885NAPRT 729/4885TDP1 924/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.